the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer

• Status: Recruiting
• Trial end date: 2022-08-12
• Target enrollment: 0
• Participant gender: All

Summary

This study is to observe and compare the effect of docetaxel plus lobaplatin induction chemotherapy combined with lopoplatin chemoradiotherapy and TPF induction chemotherapy combined with cisplatin chemoradiotherapy on dendritic cells subsets in the treatment of locally advanced head and neck squamous cell carcinoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guiyang Medical University
• Treatments: Cisplatin

Criteria

Inclusion Criteria:

1. initial treatment of advanced nasopharyngeal carcinoma Ⅲ-Ⅳ patients with pathologically confirmed (according to 2010 UICC staging, T3-4, N0-3), without evidence of distant metastasis (M0). Have measurable tumor lesions.

2. KPS≥70 points.

3. the age of 18-70 years old, male or female.

4. no major organ dysfunction; normal bone marrow function (WBC ≥4.0 × 109 / L, platelets ≥100 × 109 / L, hemoglobin ≥90g / L), normal liver function (total bilirubin, alanine aminotransferase, aspartate aminotransferase ≤1.5 times the upper limit of normal), normal renal function (creatinine ≤ 1.5 times upper limit of normal).

5. understand this study and signed informed consent

Exclusion Criteria:

1. Three months in the use of Chinese herbal medicine or immune modulators

2. distant metastasis.

3. who had received prior chemotherapy.

4. patients have physical or mental illness, and by researchers believe that patients can not be completely or fully understood in this study possible complications.

5. pregnancy (via the urine or serum β-HCG test confirmed) or during lactation. serious complications, such as uncontrolled hypertension, heart failure, diabetes and so on.